China’s war on corruption is overdue. Its allegations of bribery against GlaxoSmithKline are evidence that it is serious – and on Monday, the company acknowledged that some local executives appeared to have violated Chinese laws. But the anti-corruption battle is just one aspect of China’s drug market that foreign companies need to factor in. Healthcare reform and a push to build a strong local pharma industry are bigger long-term challenges.
manbetx3.0 早就该对腐败开战了。对葛兰素史克(GSK)的腐败指控表明，manbetx3.0 的态度是认真的。周一，该公司承认，一些manbetx3.0 本土高管违反了manbetx3.0 法律。但反腐斗争只是在manbetx3.0 药品市场中的外资医药企业需要考虑的一个因素。manbetx3.0 医疗改革和推动建立一个更强大的本土医药行业的努力，是外资药企面临的更大的长期挑战。
您已阅读23%（587字），剩余77%（1980字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。